Ss-31

Overview

SS-31 (Elamipretide) is a mitochondria-targeting tetrapeptide that binds cardiolipin in the inner mitochondrial membrane to lower oxidative stress and improve mitochondrial function. It heads off mitochondrial dysfunction, reduces reactive oxygen species, and preserves membrane integrity. The main research focus is kidney disease, cardiac dysfunction, neurodegenerative conditions, and age-related mitochondrial decline. Like most peptides, it is a research chemical needing reconstitution and subcutaneous injection, so purity and storage matter.

Quick Verdict

This is not a supplement. SS-31 is a mitochondria-targeted peptide in active clinical trials for Barth syndrome and heart failure, with genuine institutional backing and a specific binding target: cardiolipin in the inner mitochondrial membrane. Its Phase III trials for Barth syndrome narrowly missed their primary endpoints despite showing biological activity, which raises questions as much about trial design as about the drug itself.

Evidence Quality

Human trials are moderate, including Phase II/III work in Barth syndrome and heart failure with mixed primary-endpoint results but confirmed biological activity. Animal evidence is strong, with consistent mitochondrial protection across many disease models. Community reports are sparse, since the self-experimentation crowd is small and the peptide is hard to source. The central uncertainty is that those Phase III Barth syndrome trials narrowly missed their endpoints even while showing biological activity.

What the Research Shows

SS-31 is most relevant to people with diagnosed mitochondrial dysfunction or cardiomyopathy, not healthy individuals chasing optimization. Studies show significant therapeutic potential in kidney disease, improved mitochondrial function and memory, and better cardiac performance in animal models. The peptide requires subcutaneous injection and is not sold as a commercial supplement; sourcing it from research-chemical vendors means no quality assurance.

Who Should Be Cautious

This is an investigational drug. Self-administering it outside a clinical trial carries unknown risks, and anyone considering it should weigh the lack of long-term safety data against how serious their condition is.

Cited Studies

An in vitro study found SS-31 helps in kidney disease by cutting mitochondrial ROS, preventing depolarization, and blocking permeability-transition-pore formation. In mice, it reversed mitochondrial dysfunction, memory loss, and synaptic damage from inflammatory stress, and in tafazzin-knockdown (Barth syndrome) mice it improved cardiac mitochondrial function and cardiolipin profiles. A review highlighted its promise in diabetes and Alzheimer's via reduced oxidative stress and restored mitochondrial function. In a headache mouse model it eased pain and restored mitochondrial function through the Sirt3/Pgc-1α pathway. Cross-linking mass spectrometry mapped its interactions with proteins involved in ATP production and oxidative phosphorylation. It also reduced oxidative damage in a hind-limb ischemia-reperfusion model and protected neurons and aided recovery in spinal cord injury models by preserving cardiolipin. Most of this is preclinical.

Community Sentiment

Across 259 community reports, sentiment is 49% positive, 37% neutral, and 14% negative, with mention volume up a striking 850% year over year. Top reported effects are energy, mitochondrial repair, reduced inflammation, mental clarity, reduced fatigue, and a metabolic increase. The most-cited side effects are initial fatigue, exhaustion, midday sleepiness, severe tiredness, insomnia, and a crash.

Dosage Notes

The commonly cited protocol is 5 mg daily for 8 weeks. After that, users often drop to 2 to 3 mg three times a week or cycle it with MOTS-C. Around 2 mg daily is described as only minimally effective, while some run 5 mg for 10 straight days as an intensive block before maintenance. Most users report little at 2 mg but clear benefits at 5 mg, suggesting higher doses are needed. Effects tend to show up after 2 to 4 weeks, sometimes after an initial bout of fatigue, and it reportedly works best for people over 50 and when stacked with MOTS-C, NAD+, or methyl donors like B12 and TMG.

Availability

It is consistently described as expensive, especially at the 5 mg daily dose. Subcutaneous injection is standard, though some vendors push intranasal sprays of dubious value. It is sold as a research chemical and is not FDA-approved for general use outside clinical trials.

Bottom Line

SS-31 has the most legitimate clinical pedigree of this group, but it is an investigational drug aimed at serious disease, with trials that have stumbled on their endpoints. For healthy people seeking a boost, the benefit is unproven, the cost is high, and self-dosing an unapproved injectable carries real unknowns.